Abstract
Ovarian cancer is the most deadly gynecological cancer. The high rate of mortality is due to the large tumor burden with extensive metastatic lesion of the abdominal cavity. Despite initial chemosensitivity and improved surgical procedures, abdominal recurrence remains an issue and results in patients' poor prognosis. Transcriptomic and genetic studies have revealed significant genome pathologies in the primary tumors and yielded important information regarding carcinogenesis. There are, however, few studies on genetic alterations and their consequences in peritoneal metastatic tumors when compared to their matched ovarian primary tumors. We used high-density SNP arrays to investigate copy number variations in matched primary and metastatic ovarian cancer from 9 patients. Here we show that copy number variations acquired by ovarian tumors are significantly different between matched primary and metastatic tumors and these are likely due to different functional requirements. We show that these copy number variations clearly differentially affect specific pathways including the JAK/STAT and cytokine signaling pathways. While many have shown complex involvement of cytokines in the ovarian cancer environment we provide evidence that ovarian tumors have specific copy number variation differences in many of these genes.
Highlights
Epithelial Ovarian carcinoma (EOC) is the sixth most common malignancy in woman and the leading cause of death from gynecological cancer in the world [1]
One biopsy was performed from the primary tumor, and one biopsy was performed from a peritoneal metastatic lesion without the underlying peritoneal stroma
All in all our data agree well with previous copy number variations (CNV) analysis of ovarian primary tumors and this supports the new findings in the matched peritoneal metastasis [9,11]
Summary
Epithelial Ovarian carcinoma (EOC) is the sixth most common malignancy in woman and the leading cause of death from gynecological cancer in the world [1]. The poor overall survival (20 to 30% at 5 years) is due to the large tumor burden with extensive metastatic lesions of the peritoneal cavity. Efforts have been made to delineate gene expression signatures for prognostic predictions as well as chemotherapeutic responses [3,4,5,6]. These studies have attempted to provide gene predictors on disease outcome, the robustness and reproducibility of these genes lists across different patient populations have not yet been clearly established or translated to clinical practice [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
